cc-99285,lenalidomide
bms
['hodgkin', 'celmod', 'lymsm']
the trial of dr nieto and of combining a bispec. targeting nk to tumour with all nk cells for #hodgkin is great, the cr rate &gt;60% is hard to beat. how necessary is ld chemo? what about combo with len / celmods? #ash22 #ash2022 #lymsm
Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.